Transcript of the Discussion held on the Audited Financial Results (Consolidated & Standalone) of the Company for the quarter and year ended March 31, 2026, at the analyst call held on ....
AGARWALEYE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Dr. Agarwal's Healthcare crossed INR 2,000 crore revenue milestone for the first time, reporting FY26 total income of INR 2,125 crores (up 20.9%) and PAT of INR 168 crores (up 52.4%) with margins expanding. Q4 was particularly strong with EBITDA margin at 30.2%, the highest quarterly margin. The company expanded its network to 269 facilities by adding 19 new greenfield centers in Q4, and now has over 1,000 doctors serving 30 lakh+ patients. Same-store sales grew 14% (7% volume, 7% value). For FY27, the company plans to add 60 new facilities (40 surgical, 20 clinics) with INR 380-400 crore capex, with expansion focusing heavily on Delhi-NCR and West regions. A new tertiary facility in Chennai is expected by October 2026, and the merger with Dr. Agarwal's Eye Hospital is targeted for completion by Q3 FY27.
Strong execution with margin expansion and robust same-store growth demonstrates operational leverage in the greenfield expansion model. The company guiding EBITDA margins to stay stable despite aggressive expansion indicates confidence in controlling costs while scaling, which could be positive for shareholder value.